End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5.81 CNY | +0.17% | -0.34% | -1.19% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The group's high margin levels account for strong profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With a 2024 P/E ratio at 24.9 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.19% | 1B | - | ||
+38.51% | 727B | C+ | ||
-6.23% | 354B | C+ | ||
+18.78% | 328B | B- | ||
+1.35% | 277B | C+ | ||
+14.36% | 243B | B+ | ||
+7.59% | 205B | B- | ||
-5.97% | 203B | A+ | ||
+6.19% | 164B | C+ | ||
+0.31% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 002550 Stock
- Ratings Changzhou Qianhong Biopharma CO.,LTD